Actively Recruiting
Trial of THEO-260 in Ovarian Cancer Patients
Led by Theolytics Limited · Updated on 2026-04-14
44
Participants Needed
4
Research Sites
192 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.
CONDITIONS
Official Title
Trial of THEO-260 in Ovarian Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed advanced high grade serous or endometrioid cancer of the fallopian tube, primary peritoneum, or ovary
- Disease resistant or refractory to platinum chemotherapy or no suitable standard treatment available
- Life expectancy greater than 3 months
- ECOG performance status of 0 or 1
- Measurable disease according to RECIST V1.1 criteria
You will not qualify if you...
- Prior anti-cancer treatment within 28 days before first THEO-260 dose
- Previous treatment with group B adenovirus
- Participation in other investigational drug trials within 5 half-lives before first dose
- Radiation therapy within 2 weeks before first dose or planned during study
- Brain metastases or active central nervous system involvement
- Uncontrolled pleural or pericardial effusion needing frequent drainage
- History of pneumonitis or interstitial lung disease
- QTcF interval 470 ms or higher or history of serious heart rhythm problems
- Use of medications that prolong QTc interval
- Active hepatitis, tuberculosis, SARS-CoV-2, or HIV infection
- Recent serious infection requiring antibiotics
- Known allergies to study drug components
- Viral infection within 2 weeks before first dose
- Active autoimmune disease needing recent systemic treatment
- History of kidney injury or serious heart conditions
- Left ventricular ejection fraction below 50%
- Oxygen saturation below 92% on room air
- Receipt of any vaccine within 28 days before first dose of THEO-260
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Centro Integral Oncológico Clara Campal (CIOCC) Hospital
Madrid, Spain
Actively Recruiting
2
The Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
Actively Recruiting
3
Imperial College Healthcare NHS Trust, Hammersmith Hospital
London, United Kingdom
Actively Recruiting
4
Oxford University Hospitals NHS Foundation Trust, Churchill Hospital
Oxford, United Kingdom
Actively Recruiting
Research Team
C
Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here